en.Wedoany.com Reported - June 5 news, AI virtual cell platform company Baiyao Technology has recently completed a new round of financing worth tens of millions of yuan. This round of financing was led by Guoxin Venture Capital Fund, a subsidiary of China Reform Holdings Corporation, with participation from Daotong Capital and Yunqi Partners, and follow-on investments from existing shareholders Frees Fund and BV Baidu Ventures. The raised funds will be primarily used for the next-generation virtual cell algorithm models, exclusive data collection, and industrial implementation.
The AI virtual cell direction in which Baiyao Technology operates is advancing life science computing from molecular-level screening and prediction to the modeling of cell behavior, cell state changes, and dynamic responses of living systems. Traditional AI-driven drug discovery primarily focuses on target identification, molecular generation, compound screening, and efficacy prediction. However, real-life biological processes are not solely determined by single molecular interactions; factors such as the cellular environment, gene regulatory networks, perturbation conditions, differentiation pathways, disease states, and individual differences collectively influence drug responses and treatment outcomes. Since 2023, Baiyao Technology has been building a foundational AI virtual cell large model, aiming to achieve more precise analysis and prediction of cell behavior and state changes through single-cell multi-omics data, perturbation data, and clinical data. According to its official website, the company focuses on "building AI virtual cells to achieve life engineering," with its technology platform covering areas such as the Xcompass cell large model interaction platform, cell design platform, physiological and pathological simulation platform, and AI intelligent cell laboratory, striving to make cell state simulation, disease mechanism analysis, drug response prediction, and cell product design more computable, verifiable, and engineerable processes.
The use of this financing is concentrated on three lines: models, data, and industrial implementation.
Whether AI virtual cells can truly generate industrial value depends not only on the algorithm models themselves but also on high-quality data and real-world application scenarios. Public information shows that Baiyao Technology's founding team, leveraging research resources from the Institute of Zoology, Chinese Academy of Sciences, and the Beijing Institute of Stem Cell and Regenerative Medicine, has accumulated large-scale AI-ready public datasets. The company plans to implement proprietary data collection technologies to gather high-quality time-series perturbation datasets suitable for AIVC model training, while also initiating large-scale clinical data collaboration projects. Such data is particularly crucial for virtual cell models because cells are not static objects; they continuously undergo state transitions in response to drugs, gene editing, microenvironmental changes, and disease progression. Only with sufficient continuity, perturbation, and clinically relevant data can the model move from "describing the current state of a cell" to "predicting how a cell will change in the future." On the application front, Baiyao Technology is advancing implementation in scenarios such as model deployment, joint R&D of cell therapy pipelines, early target discovery, and precise stratification of clinical samples, forming a closed-loop direction of "model-data-scenario." For biomedical companies, if AI virtual cells can perform large-scale virtual simulations before in vitro experiments, there is an opportunity to pre-screen hypotheses with lower success probabilities, shorten wet-lab experimental cycles, and improve decision-making efficiency in drug R&D, cell therapy, and precision medicine projects.
From an industry evolution perspective, AI virtual cells represent a trend of AI for Life Science moving from being a tool to becoming infrastructure. Drug R&D, cell therapy, regenerative medicine, synthetic biology, and clinical stratification all require understanding the real responses of cells under complex perturbations. Relying solely on traditional experimental methods often involves long cycles, high costs, and difficulty in exhausting variables. If virtual cell models can continuously absorb multi-omics data, experimental perturbation data, and clinical validation data, they could become a foundational simulation platform for living systems used by both research institutions and enterprises. The fact that Baiyao Technology has secured continued investment from Guoxin Venture Capital Fund, Daotong Capital, Yunqi Partners, and existing shareholders indicates that capital is viewing AI virtual cells as a more fundamental life science modeling direction following AI drug discovery. Whether the company can build sustainable competitiveness in the future will depend on model generalization capabilities, exclusive data quality, wet-lab validation efficiency, commercial conversion speed in cell therapy and drug R&D scenarios, and the ability to establish a stable cycle between scientific collaborations and industrial clients.
Following the completion of this financing round, Baiyao Technology's focus will shift to algorithm model iteration, data platform construction, and industrial scenario validation. If its AIVC platform can develop reusable capabilities in cell therapy, early target discovery, clinical sample stratification, and physiological/pathological simulation, AI virtual cells have the potential to evolve from a cutting-edge scientific concept into a fundamental tool in the biomedical R&D process.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
